Multiple myeloma refractory to lenalidomide: A systematic literature review of trials and real-world evidence.
cell therapy and immunotherapy
clinical and molecular epidemiology
multiple myeloma
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
19 Jul 2024
19 Jul 2024
Historique:
received:
23
04
2024
accepted:
24
06
2024
medline:
20
7
2024
pubmed:
20
7
2024
entrez:
20
7
2024
Statut:
aheadofprint
Résumé
The growing use of frontline lenalidomide treatment in multiple myeloma (MM) is increasing the proportion of lenalidomide-refractory patients, which may limit the efficacy of subsequent lines of treatment (LOT). This systematic literature review (January 2008-October 2023) of clinical trials (CT) and real-world studies (RW) assessed treatment outcomes in adults with relapsed/refractory MM (RRMM) who were previously treated with ≥1 LOT, progressed and were lenalidomide-refractory. Medline, EMBASE and additional electronic databases were searched for articles published in English. Primary outcomes included progression-free survival (PFS), overall survival (OS) and overall/objective response rate (ORR); 24 CT and 19 RW were included. For CT, the population-weighted mean of median PFS (CT = 14) and OS (CT = 6) were shorter in the lenalidomide-refractory cohort (months: 8.8 [n = 2699] and 21.7 [n = 1066], respectively) than the intent-to-treat population (months: 13.8 [n = 5380] and 35.9 [n = 2264], respectively); the population-weighted (N = 2142) mean ORR for lenalidomide-refractory patients (CT = 18) was 56.0%. RW reported considerable variation in PFS (RW = 7), OS (RW = 8) and ORR (RW = 8); and median PFS (RW = 2; months) was lower in lenalidomide/bortezomib-refractory (5.5/5.5; n = 81/n = 25) versus lenalidomide-refractory (7.3/8.0; n = 81/n = 61) patients. These data provide evidence that clinical trials and real-world outcomes are suboptimal in lenalidomide-refractory patients with RRMM, highlighting the need to improve treatment options for this population.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : GlaxoSmithKline
ID : 221911
Informations de copyright
© 2024 GSK and The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Références
Sonneveld P, Broijl A. Treatment of relapsed and refractory multiple myeloma. Haematologica. 2016;101(4):396–406.
Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97(8):1086–1107.
Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, et al. Multiple myeloma: EHA‐ESMO Clinical Practice Guidelines for diagnosis, treatment and follow‐up. Ann Oncol. 2021;32(3):309–322.
US Food & Drug Administration. FDA approves daratumumab for multiple myeloma ineligible for autologous stem cell transplant [Internet]. 2019 [cited 2024 Jun 14]. Available from: https://www.fda.gov/drugs/resources‐information‐approved‐drugs/fda‐approves‐daratumumab‐multiple‐myeloma‐ineligible‐autologous‐stem‐cell‐transplant
Atrash S, Thompson‐Leduc P, Tai MH, Kaila S, Gray K, Ghelerter I, et al. Treatment patterns and effectiveness of patients with multiple myeloma initiating daratumumab across different lines of therapy: a real‐world chart review study. BMC Cancer. 2021;21(1):1207.
Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;390(4):301–313.
Lee JH, Kim SH. Treatment of relapsed and refractory multiple myeloma. Blood Res. 2020;55(S1):S43–S53.
Visram A, De La Torre A, White D, Su J, Masih‐Khan E, Chu M, et al. Real world data on outcomes of anti‐CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi‐institutional report from the Canadian Myeloma Research Group (CMRG) Database. Blood Cancer J. 2023;13(1):181.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta‐analysis protocols (PRISMA‐P) 2015: elaboration and explanation. BMJ. 2015;350:g7647.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.
Scottish Intercollegiate Guidelines Network. Search filters. [cited 2024 Jun 14]. Available from: https://www.sign.ac.uk/what‐we‐do/methodology/search‐filters/
Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS‐I: a tool for assessing risk of bias in non‐randomised studies of interventions. BMJ. 2016;355:i4919.
Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, et al. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open‐label, randomised, phase 3 trial. Lancet Oncol. 2021;22(6):801–812.
Sonneveld P, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, et al. Pomalidomide and dexamethasone with or without subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: updated analysis of the phase 3 Apollo study. Blood. 2021;138(Supplement 1):2747.
Moreau P, Mateos MV, Berenson JR, Weisel K, Lazzaro A, Song K, et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018;19(7):953–964.
Dimopoulos MA, Stewart AK, Masszi T, Špička I, Oriol A, Hájek R, et al. Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment. Blood Cancer J. 2017;7(4):e554.
Siegel DS, Dimopoulos MA, Ludwig H, Facon T, Goldschmidt H, Jakubowiak A, et al. Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2018;36(8):728–734.
Leleu X, Mateos M‐V, Jagannath S, Delimpasi S, Simonova M, Spicka I, et al. Effects of refractory status to lenalidomide on safety and efficacy of selinexor, bortezomib, and dexamethasone (XVd) versus bortezomib and dexamethasone (Vd) in patients with previously treated multiple myeloma. J Clin Oncol. 2021;39(Suppl 15):8024.
Grosicki S, Simonova M, Spicka I, Pour L, Kriachok I, Gavriatopoulou M, et al. Once‐per‐week selinexor, bortezomib, and dexamethasone versus twice‐per‐week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open‐label, phase 3 trial. Lancet. 2020;396(10262):1563–1573.
Dimopoulos M, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open‐label, phase 3 study. Lancet. 2020;396(10245):186–197.
Usmani SZ, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open‐label, phase 3 study. Lancet Oncol. 2022;23(1):65–76.
Usmani SZ, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, et al. Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study. Blood Adv. 2023;7(14):3739–3748.
Einsele H, Cohen AD, Delforge M, Hillengass J, Goldschmidt H, Weisel K, et al. Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta‐cel), a BCMA‐directed CAR‐T cell therapy, in lenalidomide (len)‐refractory patients (pts) with progressive multiple myeloma (MM) after 1–3 prior lines of therapy (LOT): CARTITUDE‐2, cohort A. J Clin Oncol. 2022;40(Suppl 16):8020.
Hillengass J, Cohen AD, Delforge M, Einsele H, Goldschmidt H, Weisel K, et al. MM‐183 CARTITUDE‐2 cohort A: updated clinical data and biological correlative analyses of ciltacabtagene autoleucel (cilta‐cel) in lenalidomide‐refractory patients with progressive multiple myeloma (MM) after 1–3 prior lines of therapy (LOT). Clin Lymphoma Myeloma Leuk. 2022;22:S411.
Cohen AD. Ciltacabtagene autoleucel, a B‐cell maturation antigen‐directed chimeric antigen receptor T‐cell therapy, in lenalidomide‐refractory patients with progressive multiple myeloma after 1–3 prior lines of therapy: updated results from CARTITUDE‐ 2 cohort a. Br J Haematol. 2022;197(S1):3–50.
Dhakal B, Yong K, Harrison SJ, Mateos M‐V, Moreau P, van de Donk NWCJ, et al. First phase 3 results from CARTITUDE‐4: cilta‐cel versus standard of care (PVd or DPd) in lenalidomide‐refractory multiple myeloma. J Clin Oncol. 2023;41(Suppl 17):LBA106.
San‐Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, et al. Cilta‐cel or standard care in lenalidomide‐refractory multiple myeloma. N Engl J Med. 2023;389(4):335–347.
Chanan‐Khan AA, Lentzsch S, Quach H, Horvath N, Capra M, Ovilla R, et al. Daratumumab, bortezomib and dexamethasone versus bortezomib and dexamethasone alone for relapsed or refractory multiple myeloma based on prior treatment exposure: updated efficacy analysis of CASTOR. Blood. 2016;128(22):3313.
Lentzsch S, Quach H, Chanan‐Khan AA, Horvath N, Capra M, Ovilla R, et al. Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone for relapsed/refractory multiple myeloma (RRMM) patients: an update of overall survival in CASTOR. Blood. 2017;130(Suppl 1):1852.
Spencer A, Lentzsch S, Weisel K, Avet‐Loiseau H, Mark TM, Spicka I, et al. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica. 2018;103(12):2079–2087.
Mateos MV, Sonneveld P, Hungria V, Nooka AK, Estell JA, Barreto W, et al. Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma: three‐year follow‐up of CASTOR. Clin Lymphoma Myeloma Leuk. 2020;20(8):509–518.
Weisel KC, Sonneveld P, Mateos M‐V, Hungria VTM, Spencer A, Estell J, et al. Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D‐Vd) versus bortezomib and dexamethasone (Vd) in first relapse patients (pts) with multiple myeloma (MM): four‐year update of CASTOR. Blood. 2019;134(Suppl 1):3192.
Fu WJ, Wang YF, Zhao HG, Niu T, Fang BJ, Liao AJ, et al. Efficacy and safety of pomalidomide and low‐dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single‐arm, phase 2 trial. BMC Cancer. 2022;22(1):722.
Kumar S, Sharma A, Malik PS, Gogia A, Pathak N, Sahoo RK, et al. Bendamustine in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a phase II trial. Br J Haematol. 2022;198(2):288–297.
Sonneveld P, Zweegman S, Cavo M, Nasserinejad K, Broijl A, Troia R, et al. Carfilzomib, pomalidomide, and dexamethasone as second‐line therapy for lenalidomide‐refractory multiple myeloma. HemaSphere. 2022;6(10):e786.
Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med. 2018;379(19):1811–1822.
Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, et al. Elotuzumab, pomalidomide, and dexamethasone for relapsed/refractory multiple myeloma: efficacy after additional follow‐up of the ELOQUENT‐3 study. Clin Lymphoma Myeloma Leuk. 2019;19(10):e164–e165.
Dimopoulos M‐A, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, et al. P‐193: elotuzumab plus pomalidomide/dexamethasone for relapsed/refractory multiple myeloma: final overall survival from the phase 2 ELOQUENT‐3 trial. Clin Lymphoma Myeloma Leuk. 2021;21:S143–S144.
Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, et al. Elotuzumab plus pomalidomide and dexamethasone for relapsed/refractory multiple myeloma: final overall survival analysis from the randomized phase II ELOQUENT‐3 trial. J Clin Oncol. 2023;41(3):568–578.
Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open‐label, multicentre study. Lancet Oncol. 2016;17(1):27–38.
Orlowski RZ, Moreau P, Niesvizky R, Ludwig H, Oriol A, Chng WJ, et al. Carfilzomib‐dexamethasone versus bortezomib‐dexamethasone in relapsed or refractory multiple myeloma: updated overall survival, safety, and subgroups. Clin Lymphoma Myeloma Leuk. 2019;19(8):522–530.
Puertas B, González‐Calle V, Sureda A, Moreno MJ, Oriol A, González E, et al. Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients. Haematologica. 2023;108(10):2753–2763.
Attal M, Richardson PG, Rajkumar SV, San‐Miguel J, Beksac M, Spicka I, et al. Isatuximab plus pomalidomide and low‐dose dexamethasone versus pomalidomide and low‐dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA‐MM): a randomised, multicentre, open‐label, phase 3 study. Lancet. 2019;394(10214):2096–2107.
Richardson PG, Harrison SJ, Bringhen S, Schjesvold F, Yong K, Campana F, et al. Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the phase III ICARIA‐MM study. Future Oncol. 2021;17(34):4797–4812.
Bobin A, Manier S, De Keizer J, Karlin L, Perrot A, Hulin C, et al. P891: ixazomib, pomalidomide and dexamethasone (IxPd) in relapsed or refractory multiple myeloma (RRMM) characterized with high‐risk cytogenetics. HemaSphere. 2022;6(Suppl):783–784.
Moreau P, Dimopoulos M‐A, Mikhael J, Yong K, Capra M, Facon T, et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open‐label, randomised phase 3 trial. Lancet. 2021;397(10292):2361–2371.
Martin T, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, et al. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized phase 3 study. Blood Cancer J. 2023;13(1):72.
Qiu L, Xia Z, Fu C, Chen W, Chang C, Fang B, et al. Selinexor plus low‐dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single‐arm study. BMC Med. 2022;20(1):108.
Richardson PG, Siegel DS, Vij R, Hofmeister CC, Jagannath S, Chen C, et al. Randomized, open label phase 1/2 study of pomalidomide (POM) alone or in combination with low‐dose dexamethasone (LoDex) in patients (pts) with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide (LEN) and bortezomib (BORT): phase 2 results. Blood. 2011;118(21):634.
Richardson PG, Siegel DS, Vij R, Hofmeister CC, Baz R, Jagannath S, et al. Pomalidomide alone or in combination with low‐dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014;123(12):1826–1832.
Bahlis NJ, Siegel DS, Schiller GJ, Samaras C, Sebag M, Berdeja J, et al. Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide‐based treatment in patients with multiple myeloma: updated efficacy, safety, and health‐related quality of life results from the phase 2 MM‐014 trial. Leuk Lymphoma. 2022;63(6):1407–1417.
Bahlis NJ, Samaras C, Reece D, Sebag M, Matous J, Berdeja JG, et al. MM‐371 pomalidomide, daratumumab, and dexamethasone after lenalidomide treatment in patients with relapsed or refractory multiple myeloma (RRMM): final overall survival (OS) analysis of the phase II MM‐014 study. Clin Lymphoma Myeloma Leuk. 2023;23:S494–S495.
Matsue K, Sunami K, Matsumoto M, Kuroda J, Sugiura I, Iwasaki H, et al. Pomalidomide, dexamethasone, and daratumumab in Japanese patients with relapsed or refractory multiple myeloma after lenalidomide‐based treatment. Int J Hematol. 2022;116(1):122–130.
Bhutani M, Foureau DM, Robinson M, Guo F, Fesenkova K, Atrash S, et al. A clinical and correlative study of elotuzumab, carfilzomib, lenalidomide, and dexamethasone (Elo‐KRd) for lenalidomide refractory multiple myeloma in first relapse. Clin Lymphoma Myeloma Leuk. 2023;23(7):535–544.
Yashar D, Spektor TM, Martinez D, Ghermezi M, Swift RA, Eades B, et al. A phase 2 trial of the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone for high‐risk relapsed/refractory multiple myeloma. Leuk Lymphoma. 2022;63(4):975–983.
San Miguel J, Weisel K, Moreau P, Lacy M, Song K, Delforge M, et al. Pomalidomide plus low‐dose dexamethasone versus high‐dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM‐003): a randomised, open‐label, phase 3 trial. Lancet Oncol. 2013;14(11):1055–1066.
San Miguel JF, Weisel KC, Song KW, Delforge M, Karlin L, Goldschmidt H, et al. Impact of prior treatment and depth of response on survival in MM‐003, a randomized phase 3 study comparing pomalidomide plus low‐dose dexamethasone versus high‐dose dexamethasone in relapsed/refractory multiple myeloma. Haematologica. 2015;100(10):1334–1339.
Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open‐label, phase 3 trial. Lancet Oncol. 2019;20(6):781–794.
Awada H, Hajj Ali A, Ali M, Adroja S, Mahalwar G, Kumar A, et al. Retrospective analysis of responses to second‐line treatments of multiple myeloma after disease progression in patients who underwent ASCT. J Clin Oncol. 2022;40:e20004.
Bilotti E, Vesole DH, McBride L, Schmidt L, Gao Z, Gilani M, et al. Vorinostat in combination with lenalidomide and dexamethasone in lenalidomide‐refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2016;16(10):558–562.
Bondili SK, Bagal B, Zawar A, Ventrapati P, Thorat J, Gokarn A, et al. Real‐world outcomes with generic pomalidomide in relapsed refractory multiple myeloma‐experience from a tertiary care cancer center. JCO Glob Oncol. 2021;7:361–367.
Cerchione C, Nappi D, Catalano L, Ronconi S, Cangini D, Ceccolini M, et al. Addition of carfilzomib as a third agent in lenalidomide‐refractory multiple myeloma: switching from doublet to triplet. J Clin Oncol. 2022;40(Suppl 16):e20002.
Del Giudice ML, Gozzetti A, Antonioli E, Attucci I, Pengue L, Cassano Cassano R, et al. Carfilzomib plus dexamethasone in patients with relapsed and refractory multiple myeloma: a retro‐prospective observational study. Eur J Haematol. 2022;109(4):373–380.
Dhakal B, Einsele H, Potluri R, Schecter J, Deraedt W, Lendvai N, et al. P899: real‐world assessment of treatment patterns and outcomes in patients with lenalidomide‐refractory relapsed/refractory multiple myeloma from the optum database. HemaSphere. 2022;6(Suppl):791.
Einsele H, Dhakal B, Potluri R, Schecter J, Deraedt W, Lendvai N, et al. P46 SEER‐medicare database: real‐world treatments and outcomes in patients with lenalidomide‐refractory relapsed multiple myeloma treated with 1–3 prior lines of therapy, including a PI and IMiD. HemaSphere. 2023;7(Suppl):36.
Goldsmith SR, Fiala MA, Wang B, Schroeder MA, Wildes TM, Ghobadi A, et al. DCEP and bendamustine/prednisone as salvage therapy for quad‐ and penta‐refractory multiple myeloma. Ann Hematol. 2020;99(5):1041–1048.
Gross Z, Rahbari A, Wirtschafter E, Spektor TM, Udd KA, Bujarski S, et al. Elotuzumab and dexamethasone for relapsed or refractory multiple myeloma patients: a retrospective study. Eur J Haematol. 2018;100(6):621–623.
Ho M, Zanwar S, Kapoor P, Gertz M, Lacy M, Dispenzieri A, et al. The effect of duration of lenalidomide maintenance and outcomes of different salvage regimens in patients with multiple myeloma (MM). Blood Cancer J. 2021;11(9):158.
Hung YC, Gau JP, Huang SY, Ko BS, Teng CJ. Pomalidomide and dexamethasone are effective in relapsed or refractory multiple myeloma in a real‐life setting: a multicenter retrospective study in Taiwan. Front Oncol. 2021;11:695410.
Jung KS, Kim K, Kim HJ, Kim SH, Lee JO, Kim JS, et al. Analysis of the efficacy of thalidomide plus dexamethasone‐based regimens in patients with relapsed/refractory multiple myeloma who received prior chemotherapy, including bortezomib and lenalidomide: KMM‐166 study. Clin Lymphoma Myeloma Leuk. 2020;20(2):e97–e104.
Lau IJ, Smith D, Aitchison R, Blesing N, Roberts P, Peniket A, et al. Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide. Ann Hematol. 2015;94(4):643–649.
Matsumura‐Kimoto Y, Kuroda J, Kaneko H, Kamitsuji Y, Fuchida SI, Nakaya A, et al. Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum. Int J Hematol. 2018;107(5):541–550.
Onda Y, Kanda J, Kaneko H, Shimura Y, Fuchida SI, Nakaya A, et al. Real‐world effectiveness and safety analysis of carfilzomib‐lenalidomide‐dexamethasone and carfilzomib‐dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis. Ther Adv Hematol. 2022;13:20406207221104584.
Reece DE, Masih‐Khan E, Atenafu EG, Jimenez‐Zepeda VH, McCurdy A, Song K, et al. Retrospective study of treatment patterns and outcomes post‐lenalidomide for multiple myeloma in Canada. Eur J Haematol. 2021;107(4):416–427.
Rocchi S, Tacchetti P, Pantani L, Mancuso K, Rizzello I, di Giovanni BC, et al. A real‐world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma. Hematol Oncol. 2021;39(1):41–50.
Takakuwa T, Yamamura R, Ohta K, Kaneko H, Imada K, Nakaya A, et al. Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: a multicenter retrospective analysis. Eur J Haematol. 2021;106(4):555–562.
Trudel S, Tessoulin B, Jullien M, Blin N, Gastinne T, Mahé B, et al. Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real‐life setting: a single‐center retrospective study. Ann Hematol. 2019;98(6):1441–1447.
Mateos MV, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, et al. LocoMMotion: a prospective, non‐interventional, multinational study of real‐life current standards of care in patients with relapsed and/or refractory multiple myeloma. Leukemia. 2022;36(5):1371–1376.
McCurdy A, Gul E, Reece D, Venner CP, White D, Su J, et al. Second line treatment and outcomes of patients with multiple myeloma: a real world multi‐institutional report from the Canadian Myeloma Research Group (CMRG) database. Blood. 2023;142:3364.
Richardson PG, Hofmeister CC, Raje NS, Siegel DS, Lonial S, Laubach J, et al. Pomalidomide, bortezomib and low‐dose dexamethasone in lenalidomide‐refractory and proteasome inhibitor‐exposed myeloma. Leukemia. 2017;31(12):2695–2701.
Mian H, McCurdy A, Giri S, Grant S, Rochwerg B, Winks E, et al. The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: a systematic review. Blood Cancer J. 2023;13(1):6.
Durie BGM, Hoering A, Sexton R, Abidi MH, Epstein J, Rajkumar SV, et al. Longer term follow‐up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J. 2020;10(5):53.
Schjesvold FH, Dimopoulos MA, Delimpasi S, Robak P, Coriu D, Legiec W, et al. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head‐to‐head, open‐label, phase 3 study. Lancet Haematol. 2022;9(2):e98–e110.
Schjesvold FH, Bakker NA, Sonneveld P. Authors' reply: perspective: the approval and withdrawal of melphalan flufenamide (melflufen): implications for the state of the FDA. Transl Oncol. 2022;25:101528.
Facon T, Kumar SK, Plesner T, Orlowski RZ, Moreau P, Bahlis N, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open‐label, phase 3 trial. Lancet Oncol. 2021;22(11):1582–1596.
Leow CC, Low MSY. Targeted therapies for multiple myeloma. J Pers Med. 2021;11(5):334.
Rodriguez‐Otero P, van de Donk N, Pillarisetti K, Cornax I, Vishwamitra D, Gray K, et al. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review. Blood Cancer J. 2024;14(1):24.
Kleber M, Ntanasis‐Stathopoulos I, Terpos E. BCMA in multiple myeloma‐a promising key to therapy. J Clin Med. 2021;10(18):4088.
Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM‐2): a two‐arm, randomised, open‐label, phase 2 study. Lancet Oncol. 2020;21(2):207–221.
Richardson PG, Lee HC, Abdallah AO, Cohen AD, Kapoor P, Voorhees PM, et al. Single‐agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM‐2 study. Blood Cancer J. 2020;10(10):106.
Clinicaltrials.gov.identifier NCT03601078. An efficacy and safety study of bb2121 in subjects with relapsed and refractory multiple myeloma and in subjects with high‐risk multiple myeloma (KarMMa‐2) [Internet]. 2024. Bethesda (MD): National Library of Medicine (US). [cited 2024 Jun 14]. Available from: https://clinicaltrials.gov/study/NCT03601078
Usmani S, Patel K, Hari P, Berdeja J, Alsina M, Vij R, et al. KarMMa‐2 Cohort 2a: efficacy and safety of idecabtagene vicleucel in clinical high‐risk multiple myeloma patients with early relapse after frontline autologous stem cell transplantation. Blood. 2022;140(Suppl 1):875–877.
Tanenbaum B, Miett T, Patel SA. The emerging therapeutic landscape of relapsed/refractory multiple myeloma. Ann Hematol. 2023;102(1):1–11.
US Food & Drug Administration. FDA approves teclistamab‐cqyv for relapsed or refractory multiple myeloma [Internet]. 2022 [cited 2024 Jun 14]. Available from: https://www.fda.gov/drugs/resources‐information‐approved‐drugs/fda‐approves‐teclistamab‐cqyv‐relapsed‐or‐refractory‐multiple‐myeloma
Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San‐Miguel JF, Oriol A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495–505.
US Food & Drug Administration. FDA grants accelerated approval to elranatamab‐bcmm for multiple myeloma [Internet]. 2023 [cited 2024 Jun 14]. Available from: https://www.fda.gov/drugs/resources‐information‐approved‐drugs/fda‐grants‐accelerated‐approval‐elranatamab‐bcmm‐multiple‐myeloma
US Food & Drug Administration. FDA grants accelerated approval to talquetamab‐tgvs for relapsed or refractory multiple myeloma [Internet]. 2023 [cited 2024 Jun 14]. Available from: https://www.fda.gov/drugs/resources‐information‐approved‐drugs/fda‐grants‐accelerated‐approval‐talquetamab‐tgvs‐relapsed‐or‐refractory‐multiple‐myeloma
Mateos M‐V, Bahlis NJ, Costa LJ, Perrot A, Pei L, Rubin ML, et al. MajesTEC‐3: randomized, phase 3 study of teclistamab plus daratumumab versus investigator's choice of daratumumab, pomalidomide, and dexamethasone or daratumumab, bortezomib, and dexamethasone in patients with relapsed/refractory multiple myeloma. J Clin Oncol. 2022;40(Suppl 16):TPS8072.
Clinicaltrials.gov.identifier NCT05020236. MagnetisMM‐5: study of elranatamab (PF‐06863135) monotherapy and elranatamab + daratumumab versus daratumumab + pomalidomide + dexamethasone in participants with relapsed/refractory multiple myeloma (MAGNETISMM‐5) [Internet]. 2024. Bethesda (MD): National Library of Medicine (US). [cited 2024 Jun 14]. Available from: https://www.clinicaltrials.gov/study/NCT05020236
Cohen YC, Moreau P, Tolbert J, Qin X, Ma X, Vieyra D, et al. MonumenTAL‐3: phase 3 trial of talquetamab + daratumumab ± pomalidomide versus daratumumab + pomalidomide + dexamethasone in relapsed/refractory multiple myeloma following ≥1 prior line of therapy. Blood. 2022;140(Suppl 1):4418–4419.
Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, et al. Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2024. Online ahead of print. https://doi.org/10.1056/NEJMoa2405090
Dimopoulos MA, Beksac M, Pour L, Delimpasi S, Vorobyev V, Quach H, et al. Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma. N Engl J Med. 2024. Online ahead of print. https://doi.org/10.1056/NEJMoa2403407
Stewart L, Moher D, Shekelle P. Why prospective registration of systematic reviews makes sense. Syst Rev. 2012;1:7.
Richardson PG, San Miguel JF, Moreau P, Hajek R, Dimopoulos MA, Laubach JP, et al. Interpreting clinical trial data in multiple myeloma: translating findings to the real‐world setting. Blood Cancer J. 2018;8(11):109.